597 related articles for article (PubMed ID: 26435033)
1. Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study.
Manski-Nankervis J; Yates CJ; Blackberry I; Furler J; Ginnivan L; Cohen N; Jenkins A; Vasanthakumar S; Gorelik A; Young D; Best J; O'Neal D
Diabet Med; 2016 Jun; 33(6):803-11. PubMed ID: 26435033
[TBL] [Abstract][Full Text] [Related]
2. An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study.
Blackberry ID; Furler JS; Ginnivan LE; Manski-Nankervis JA; Jenkins A; Cohen N; Best JD; Young D; Liew D; Ward G; O'Neal DN
Diabetes Res Clin Pract; 2014 Nov; 106(2):247-55. PubMed ID: 25271117
[TBL] [Abstract][Full Text] [Related]
3. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes.
Hanefeld M; Koehler C; Hoffmann C; Wilhelm K; Kamke W; Gerstein H
Diabet Med; 2010 Feb; 27(2):175-80. PubMed ID: 20546261
[TBL] [Abstract][Full Text] [Related]
4. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
[TBL] [Abstract][Full Text] [Related]
5. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
[TBL] [Abstract][Full Text] [Related]
6. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
7. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.
Ohta A; Arai K; Nishine A; Sada Y; Kato H; Fukuda H; Asai S; Nagai Y; Katabami T; Tanaka Y
Endocr J; 2013; 60(2):173-7. PubMed ID: 23047542
[TBL] [Abstract][Full Text] [Related]
8. Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.
Zhou J; Zheng F; Guo X; Yang H; Zhang M; Tian H; Guo L; Li Q; Mo Y; Jia W
Diabetes Metab Res Rev; 2015 Oct; 31(7):725-33. PubMed ID: 25952634
[TBL] [Abstract][Full Text] [Related]
9. Insulin during pregnancy, labour and delivery.
de Valk HW; Visser GH
Best Pract Res Clin Obstet Gynaecol; 2011 Feb; 25(1):65-76. PubMed ID: 21186142
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
[TBL] [Abstract][Full Text] [Related]
11. Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study.
Ilany J; Bhandari H; Nabriski D; Toledano Y; Konvalina N; Cohen O
Diabetes Obes Metab; 2018 May; 20(5):1186-1192. PubMed ID: 29316176
[TBL] [Abstract][Full Text] [Related]
12. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
13. Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study.
Del Prato S; Nicolucci A; Lovagnini-Scher AC; Turco S; Leotta S; Vespasiani G;
Diabetes Technol Ther; 2012 Feb; 14(2):175-82. PubMed ID: 22013886
[TBL] [Abstract][Full Text] [Related]
14. [Optimised glycaemic control and dose titration with insulin glargine (Lantus) by general practitioners in Switzerland: results of the OPTI-LAN Postmarketing Study].
Spirk D; Lareida J; Scheidegger K; Diem P
Praxis (Bern 1994); 2009 Mar; 98(6):315-20. PubMed ID: 19291638
[TBL] [Abstract][Full Text] [Related]
15. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes.
Derosa G; Franzetti I; Querci F; Romano D; D'Angelo A; Maffioli P
Diabetes Obes Metab; 2015 Jun; 17(6):554-559. PubMed ID: 25694300
[TBL] [Abstract][Full Text] [Related]
16. Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.
Owens DR; Landgraf W; Frier BM; Zhang M; Home PD; Meneghini L; Bolli GB
Diabetes Obes Metab; 2019 Feb; 21(2):321-329. PubMed ID: 30520217
[TBL] [Abstract][Full Text] [Related]
17. Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.
Umpierrez GE; O'Neal D; DiGenio A; Goldenberg R; Hernandez-Triana E; Lin J; Park CY; Renard E; Kovatchev B
Diabetes Obes Metab; 2017 Sep; 19(9):1317-1321. PubMed ID: 28256054
[TBL] [Abstract][Full Text] [Related]
18. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Ahrén B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark BO; Sjöberg S; Pehrsson NG
BMJ; 2015 Oct; 351():h5364. PubMed ID: 26512041
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
Lin S; Chen M; Chen W; Lin K; Mu P; Zhu B; Xu W; Wang M; Weng J; Zeng L
J Diabetes Res; 2018; 2018():2791584. PubMed ID: 30420969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]